# OnCo record paper-libretto-431-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-libretto-431-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-libretto-431-nejm-2023" ;
  schema:name "LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer"@en ;
  schema:description "Given as first treatment, selpercatinib more than doubled the time to progression compared with platinum-pemetrexed chemotherapy plus pembrolizumab in RET fusion-positive lung cancer, and protected against brain metastases."@en ;
  schema:url <https://onco.cc/key-papers/paper-libretto-431-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2309457>, <https://pubmed.ncbi.nlm.nih.gov/37870973/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2309457> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Zhou C, Solomon B, Loong HH, et al." ;
  onco:cancers <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/selpercatinib/> ;
  onco:trials <https://onco.cc/trials/libretto-431/> ;
  onco:journals <https://onco.cc/journals/nejm/> .